{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096985","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.142387+00:00","generated_at":"2026-05-31T09:17:54.557399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kodiak Sciences Q2 net loss $45.1M, cash $219.2M; three Phase  trials enrolling","bullets":["Net loss $45.1M ($0.86/sh) vs $80.2M ($1.53/sh) in Q2 2023; R&D expense down 52% to $32.5M.","Cash and cash equivalents $219.2M; company believes funds operations into 2026.","Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) actively enrolling; Phase 1b APEX (KSI-101) enrolling.","Appointed Dolly Chang (ex-Genentech) as CSO; promoted Almas Qudrat (CQO), Wayne To (CTO), Pablo Velazquez-Martin (CMO).","Investor Day scheduled for September 23, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096985","json":"https://secwatch.observer/filing/0000950170-24-096985.json","markdown":"https://secwatch.observer/filing/0000950170-24-096985.md","text":"https://secwatch.observer/filing/0000950170-24-096985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024096985/0000950170-24-096985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024096985/kod-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:17:54.557399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}